https://orcid.org/0000-0002-0807-7139
Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ana Neves, Luísa Viveiros, Veronica Venturelli & David A Isenberg. (2023) Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities. Research and Reports in Urology 15, pages 333-353.
Read now
Read now
Yuan Wang, Chengfeng Ma, Zhanbing Ma, Mengyi Yang, Jing Pu, Xiuhui Ma, Xi Wu, Liang Peng, Zhenghao Huo & Jie Dang. (2023) Identification and Clinical Correlation Analysis of IFI44 in Systemic Lupus Erythematosus Combined with Bioinformatics and Immune Infiltration Analysis. Journal of Inflammation Research 16, pages 3219-3231.
Read now
Read now
Marlene Plüß, Silvia Piantoni, Björn Tampe, Alfred H. J. Kim & Peter Korsten. (2022) Belimumab for systemic lupus erythematosus – Focus on lupus nephritis. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Abdullah Ali Ahmed, Naureen Osman & Richard Furie. (2022) An evaluation of anifrolumab for use in adults with systemic lupus erythematosus. Expert Review of Clinical Immunology 18:11, pages 1095-1106.
Read now
Read now
Aliki I. Venetsanopoulou, Paraskevi V. Voulgari & Alexandros A. Drosos. (2022) Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Review of Clinical Immunology 18:5, pages 485-493.
Read now
Read now
Christophe Richez & Marie-Elise Truchetet. (2021) Evaluating filgotinib for the treatment of rheumatoid arthritis. Expert Opinion on Pharmacotherapy 22:18, pages 2435-2444.
Read now
Read now
Articles from other publishers (37)
Yusuke Miyazaki, Masashi Funada, Shingo Nakayamada, Koshiro Sonomoto, Hiroaki Tanaka, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Ayako Yamaguchi, Ippei Miyagawa, Yasuyuki Todoroki, Masanobu Ueno & Yoshiya Tanaka. (2023) Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology.
Crossref
Crossref
Tong Li, Xianjing Yang, Juan Zhu, Ying Liu, Xiaobao Jin, Gong Chen & Lianbao Ye. (2023) Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases. International Immunopharmacology 122, pages 110660.
Crossref
Crossref
Chandra Mohan, Ting Zhang & Chaim Putterman. (2023) Pathogenic cellular and molecular mediators in lupus nephritis. Nature Reviews Nephrology 19:8, pages 491-508.
Crossref
Crossref
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edward C Keystone, Peter Nash, Mark Genovese, Franziska Matzkies, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Lei Ye, Qi Gong, Chantal Tasset & Tsutomu Takeuchi. (2023) Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results. Modern Rheumatology 33:4, pages 668-679.
Crossref
Crossref
Shingo Nakayamada & Yoshiya Tanaka. (2023) Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus. Biomolecules 13:6, pages 960.
Crossref
Crossref
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I. White, David W. Boulton & Alexander MacDonald. (2023) Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical Pharmacokinetics 62:5, pages 655-671.
Crossref
Crossref
Sarah K. Wise, Cecelia Damask, Lauren T. Roland, Charles Ebert, Joshua M. Levy, Sandra Lin, Amber Luong, Kenneth Rodriguez, Ahmad R. Sedaghat, Elina Toskala, Jennifer Villwock, Baharudin Abdullah, Cezmi Akdis, Jeremiah A. Alt, Ignacio J. Ansotegui, Antoine Azar, Fuad Baroody, Michael S. Benninger, Jonathan Bernstein, Christopher Brook, Raewyn Campbell, Thomas Casale, Mohamad R. Chaaban, Fook Tim Chew, Jeffrey Chambliss, Antonella Cianferoni, Adnan Custovic, Elizabeth Mahoney Davis, John M. DelGaudio, Anne K. Ellis, Carrie Flanagan, Wytske J. Fokkens, Christine Franzese, Matthew Greenhawt, Amarbir Gill, Ashleigh Halderman, Jens M. Hohlfeld, Cristoforo Incorvaia, Stephanie A. Joe, Shyam Joshi, Merin Elizabeth Kuruvilla, Jean Kim, Adam M. Klein, Helene J. Krouse, Edward C. Kuan, David Lang, Desiree Larenas‐Linnemann, Adrienne M. Laury, Matt Lechner, Stella E. Lee, Victoria S. Lee, Patricia Loftus, Sonya Marcus, Haidy Marzouk, Jose Mattos, Edward McCoul, Erik Melen, James W. Mims, Joaquim Mullol, Jayakar V. Nayak, John Oppenheimer, Richard R. Orlandi, Katie Phillips, Michael Platt, Murugappan RamanathanJrJr, Mallory Raymond, Chae‐Seo Rhee, Sietze Reitsma, Matthew Ryan, Joaquin Sastre, Rodney J. Schlosser, Theodore A. Schuman, Marcus S. Shaker, Aziz Sheikh, Kristine A. Smith, Michael B. Soyka, Masayoshi Takashima, Monica Tang, Pongsakorn Tantilipikorn, Malcolm B. Taw, Jody Tversky, Matthew A. Tyler, Maria C. Veling, Dana Wallace, De Yun Wang, Andrew White & Luo Zhang. (2023) International consensus statement on allergy and rhinology: Allergic rhinitis – 2023. International Forum of Allergy & Rhinology 13:4, pages 293-859.
Crossref
Crossref
Daniele Accapezzato, Rosalba Caccavale, Maria Pia Paroli, Chiara Gioia, Bich Lien Nguyen, Luca Spadea & Marino Paroli. (2023) Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. International Journal of Molecular Sciences 24:7, pages 6578.
Crossref
Crossref
Yoshiya Tanaka, Tatsuya Atsumi, Masato Okada, Tomoya Miyamura, Tomonori Ishii, Susumu Nishiyama, Ryutaro Matsumura, Nobuya Hayashi, Gabriel Abreu, Raj Tummala, Eric F Morand & Tsutomu Takeuchi. (2023) The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis. Modern Rheumatology 33:1, pages 134-144.
Crossref
Crossref
Yoshiya Tanaka. (2022) Systemic lupus erythematosus. Best Practice & Research Clinical Rheumatology 36:4, pages 101814.
Crossref
Crossref
Yoshiya Tanaka, Masaki Kusuda & Yoshiyuki Yamaguchi. (2022) Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease. Modern Rheumatology.
Crossref
Crossref
Eiji Suzuki, Xian K. Zhang, Makiko Yashiro-Furuya, Tomoyuki Asano, Takashi Kanno, Hiroko Kobayashi, Kiyoshi Migita & Hiromasa Ohira. (2022) The expression of Ets-1 and Fli-1 is associated with interferon-inducible genes in peripheral blood mononuclear cells from Japanese patients with systemic lupus erythematosus. Medicine 101:45, pages e31522.
Crossref
Crossref
Sylvia Raftopoulou, Anna Rapti, Dimitris Karathanasis, Maria Eleftheria Evangelopoulos & Clio P. Mavragani. (2022) The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement. Frontiers in Neurology 13.
Crossref
Crossref
Tina YuXuan Luo, Yonghong Shi, Guizhi Wang & David E. Spaner. (2022) Enhanced IFN Sensing by Aggressive Chronic Lymphocytic Leukemia Cells. The Journal of Immunology 209:9, pages 1662-1673.
Crossref
Crossref
Daniel J Wallace, Tatsuya Atsumi, Mark Daniels, Anne Hammer, Paige MeizlikHolly Quasny, Andreas Schwarting, Fengchun Zhang & David A Roth. (2022) Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data. Lupus 31:13, pages 1649-1659.
Crossref
Crossref
Chen Yu, Ping Li, Xin Dang, Xuan Zhang, Yonghui Mao & Xiangmei Chen. (2022) Lupus nephritis: new progress in diagnosis and treatment. Journal of Autoimmunity 132, pages 102871.
Crossref
Crossref
Yen Lin Chia, Raj Tummala, Tu H. Mai, Tomas Rouse, Katie Streicher, Wendy I. White, Eric F. Morand & Richard A. Furie. (2022) Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus. The Journal of Clinical Pharmacology 62:9, pages 1094-1105.
Crossref
Crossref
Kyriakos A. Kirou, Maria Dall`Era, Cynthia Aranow & Hans-Joachim Anders. (2022) Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Frontiers in Immunology 13.
Crossref
Crossref
Zutong Li, Zhilong Wang, Tian Sun, Shanshan Liu, Shuai Ding & Lingyun Sun. (2022) Identifying key genes in CD4+ T cells of systemic lupus erythematosus by integrated bioinformatics analysis. Frontiers in Genetics 13.
Crossref
Crossref
Yiduo Sun, Jin Lin & Weiqian Chen. (2022) Type I Interferons in the Pathogenesis and Treatment of Sjögren’s Syndrome: An Update. EMJ Rheumatology, pages 59-69.
Crossref
Crossref
Ian N Bruce, Sarowar Golam, Jason Steenkamp, Pearl Wang, Evelyn Worthington, Barnabas Desta, Konstantina Psachoulia, Wilma Erhardt & Raj Tummala. (2022) Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. Journal of Comparative Effectiveness Research 11:10, pages 765-777.
Crossref
Crossref
Ian N Bruce, Richard A Furie, Eric F Morand, Susan Manzi, Yoshiya Tanaka, Kenneth C. Kalunian, Joan T Merrill, Patricia Puzio, Emmanuelle Maho, Christi Kleoudis, Marius Albulescu, Micki Hultquist & Raj Tummala. (2022) Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases 81:7, pages 962-969.
Crossref
Crossref
Edward M Vital, Joan T Merrill, Eric F Morand, Richard A Furie, Ian N Bruce, Yoshiya Tanaka, Susan Manzi, Kenneth C Kalunian, Rubana N Kalyani, Katie Streicher, Gabriel Abreu & Raj Tummala. (2022) Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases 81:7, pages 951-961.
Crossref
Crossref
Yvette N. Lamb. (2022) Anifrolumab in systemic lupus erythematosus: a profile of its use. Drugs & Therapy Perspectives 38:7, pages 293-300.
Crossref
Crossref
Sarika Chaudhari, Grace S. Pham, Calvin D. Brooks, Viet Q. Dinh, Cassandra M. Young-Stubbs, Caroline G. Shimoura & Keisa W. Mathis. (2022) Should Renal Inflammation Be Targeted While Treating Hypertension?. Frontiers in Physiology 13.
Crossref
Crossref
Sarit Sekhar Pattanaik, Aditya K Panda, Abhijit Pati, Sunali Padhi, Rina Tripathy, Saumya Ranjan Tripathy, Manoj Kumar Parida & Bidyut Kumar Das. (2022) Role of interleukin-6 and interferon-α in systemic lupus erythematosus: A case–control study and meta-analysis. Lupus, pages 096120332211025.
Crossref
Crossref
Yen Lin Chia, Jianchun Zhang, Raj Tummala, Tomas Rouse, Richard A Furie & Eric F Morand. (2022) Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology 61:5, pages 1900-1910.
Crossref
Crossref
Hisashi MurataMakoto KinoshitaYoshiaki Yasumizu, Daisuke MotookaShohei BeppuNaoyuki ShiraishiYasuko SugiyamaKeigo KiharaSatoru TadaToru KodaHachiro KonakaHyota TakamatsuAtsushi KumanogohTatsusada OkunoHideki Mochizuki. (2022) Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder. Neurology Neuroimmunology & Neuroinflammation 9:3.
Crossref
Crossref
Yuichi Ishikawa, Kazuhisa Nakano, Kei Tokutsu, Shingo Nakayamada, Shinya Matsuda, Kiyohide Fushimi & Yoshiya Tanaka. (2022) Short-Term Prognostic Factors in Hospitalized Herpes Zoster Patients and Its Associated Cerebro-Cardiovascular Events: A Nationwide Retrospective Cohort in Japan. Frontiers in Medicine 9.
Crossref
Crossref
Katsunori Suzuki & Yoshiya Tanaka. (2022) Infections associated with systemic lupus erythematosus: Tackling two devils in the deep blue sea. Indian Journal of Rheumatology 0:0, pages 0.
Crossref
Crossref
Rawish Fatima, Yasmin Khader, Wade Lee-Smith, Anu Garg, Nezam Altorok & Muhammad Aziz. (2022) Safety and Efficacy of Anifrolumab for Systemic Lupus Erythematosus: Network Meta-analysis. American Journal of Therapeutics Publish Ahead of Print.
Crossref
Crossref
Yoshiya Tanaka. (2021) Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology 60:Supplement_6, pages vi12-vi20.
Crossref
Crossref
E. L. Nasonov, A. S. Avdeeva & T. V. Popkova. (2021) New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Rheumatology Science and Practice 59:5, pages 537-546.
Crossref
Crossref
George E. Fragoulis, James Brock, Neil Basu, Iain B. McInnes & Stefan Siebert. (2021) The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. Journal of Allergy and Clinical Immunology 148:4, pages 941-952.
Crossref
Crossref
Frédéric De Ceuninck, Fanny Duguet, Audrey Aussy, Laurence Laigle & Philippe Moingeon. (2021) IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases. Drug Discovery Today 26:10, pages 2465-2473.
Crossref
Crossref
Philippe Georgel. (2021) Crosstalk between Interleukin-1β and Type I Interferons Signaling in Autoinflammatory Diseases. Cells 10:5, pages 1134.
Crossref
Crossref
Hiroshi Furukawa, Shomi Oka, Takashi Higuchi, Kota Shimada, Atsushi Hashimoto, Toshihiro Matsui & Shigeto Tohma. (2021) Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2110225.
Crossref
Crossref